search for




 

Methotrexate-induced Oral Mucositis
J Oral Med Pain 2015;40:82-87
Published online June 30, 2015
© 2015 Korean Academy of Orofacial Pain and Oral Medicine

Hye-Jin Lee, Jeong-Seung Kwon, Young-Chan Choi, Hyung Joon Ahn

Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentisty, Seoul, Korea
Correspondence to: Hyung Joon Ahn
Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentistry, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea
Tel: +82-2-2228-3112
Fax: +82-2-393-5673
E-mail: hjahn@yuhs.ac
Received March 30, 2015; Revised April 14, 2015; Accepted April 27, 2015.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Methotrexate (MTX) is a chemotherapeutic agent that is used to treat a host of malignancies. But recently, MTX has also been used as a therapeutic agent for chronic inflammatory disorders such as rheumatoid arthritis, psoriasis, and systemic lupus erythematosus. However, MTX is an antimetabolite that affects rapidly dividing normal cells such as oral mucosal epithelial cells, gastrointestinal epithelial cells, and bone marrow cells—which explains why oral mucositis is often an initial manifestation of MTX toxicity. Because oral lesions are frequently initially presented in dental clinics, dentists should consider the possibility of adverse drug reactions in the differential diagnoses of oral lesions through a meticulous collection of patients’ medical histories. In this report, we examine patients who suffered from oral ulcerative lesions upon diagnosis of MTX-induced oral mucositis. Then, we suggest approaches for the diagnosis and treatment of MTX-induced oral mucositis through a review of literature.
Keywords : Folic acid deficiency; Methotrexate; Oral mucositis; Rheumatoid arthritis


September 2017, 42 (3)